Core Viewpoint - China Resources Pharmaceutical (03320) has established a limited partnership agreement to create a proposed fund of RMB 500 million, focusing on investments in high-growth companies in synthetic biology, innovative drugs, and biotechnology sectors [1] Group 1: Fund Details - The fund will be established with China Resources Pharmaceutical (Shantou) as the general partner, and China Resources Double Crane and China Resources Pharmaceutical Investment as limited partners, all of which are subsidiaries of the company [1] - The total commitment from the group will be RMB 123 million, accounting for approximately 24.6% of the total fund commitment [1] - Shenzhen China Resources Capital will be appointed as the fund manager [1] Group 2: Strategic Objectives - Establishing the fund aligns with the company's strategic development direction in synthetic biology [1] - The group aims to build a synthetic biology industrialization platform in Hohhot, optimizing its strategic layout in key related areas [1] - The fund is expected to enhance investment channels in the synthetic biology industry, promote innovation incubation, accelerate product technology collaboration, and secure commercialization rights for products [1]

Core Viewpoint - China Resources Pharmaceutical (03320.HK) announced the establishment of a proposed fund with a scale of RMB 500 million, focusing on investments in high-growth enterprises in synthetic biology, innovative drugs, and biotechnology sectors [1] Group 1: Fund Details - The fund will be established through a limited partnership agreement involving China Resources Pharmaceutical (Shantou) as the general partner, China Resources Double Crane as a limited partner, and China Resources Pharmaceutical Investment as a limited partner [1] - The total commitment from the group will be RMB 123 million, representing approximately 24.6% of the total fund commitment [1] - Shenzhen China Resources Capital will be appointed as the fund manager [1] Group 2: Investment Focus - The fund aims to invest primarily in high-growth enterprises within the fields of synthetic biology, innovative drugs, and biotechnology [1]

Core Viewpoint - China Resources Pharmaceutical (03320) has established a limited partnership agreement to create a proposed fund of RMB 500 million, focusing on investments in high-growth companies in synthetic biology, innovative drugs, and biotechnology sectors [1] Group 1: Fund Details - The fund will be established with contributions from China Resources Pharmaceutical (Shantou) as the general partner, China Resources Double Crane as a limited partner, and China Resources Pharmaceutical Investment as a limited partner, all of which are subsidiaries of the company [1] - The total commitment from the group is RMB 123 million, accounting for approximately 24.6% of the total fund commitment [1] - Shenzhen China Resources Capital will be appointed as the fund manager [1] Group 2: Strategic Objectives - Establishing the fund aligns with the company's strategic direction in synthetic biology [1] - The group aims to build a synthetic biology industrialization platform in Hohhot, optimizing its strategic layout in key areas [1] - The fund is expected to enhance investment channels in synthetic biology, promote innovation incubation, accelerate product technology collaboration, and secure commercialization rights for products [1] - After the fund is established, it will be accounted for as equity investment in the company's consolidated financial statements [1]

（股份代號：3320） 關連交易 成立基金 董事會欣然宣佈，於二零二五年十月二十九日，華潤醫藥（汕頭）（作為普通 合夥人）、華潤雙鶴（作為有限合夥人）以及華潤醫藥投資（作為有限合夥人） （各自為本公司之附屬公司）與其他合夥人就成立擬議規模為人民幣5億元 之基金訂立有限合夥協議。基金將主要從事合成生物學、創新藥物及生物技 術領域的高增長企業投資。本集團擬承諾出資總額將為人民幣1.23億元，約 佔基金承諾出資總額的24.6%。基金於成立後將不會入賬為本公司之附屬公 司。深圳華潤資本將獲委託為基金之基金管理人。 於本公告之日，一名合夥人漢威華酉汕頭為華潤投資（天津）的全資附屬公 司，而華潤投資（天津）由本公司控股股東華潤集團最終持有。因此，漢威華 酉汕頭構成了本公司的關連人士，而有限合夥協議和其項下擬進行的交易 構成本公司於上市規則第14A章項下的關連交易。 1 由於上市規則第14.07條項下有關成立基金的一項或多項適用百分比率超過 0.1%但均低於5%，故根據上市規則第14A章，有限合夥協議及其項下擬進行 的交易僅須遵守申報及公告規定，惟獲豁免遵守獨立股東批准規定。 香港交易及結算所有限公司及香港聯合交易所有限公 ...

Core Viewpoint - China Resources Pharmaceutical (03320) announced that its subsidiary, China Resources Boya Bio (300294), achieved a total operating revenue of 1.474 billion RMB for the nine months ending September 30, 2025, representing a year-on-year growth of 18.4%. However, the net profit was 343 million RMB, showing a year-on-year decline of 16.8% [1] Summary by Category - **Revenue Performance** - China Resources Boya Bio reported total operating revenue of 1.474 billion RMB for the nine months ending September 30, 2025, which is an increase of 18.4% compared to the previous year [1] - **Profitability** - The net profit for the same period was 343 million RMB, reflecting a decrease of 16.8% year-on-year [1]

Group 1 - The core viewpoint of the article highlights the financial performance of China Resources Pharmaceutical's subsidiary, China Resources Boya Biopharmaceutical, for the nine months ending September 30, 2025, showing a revenue increase but a decline in net profit [1] Group 2 - The company's operating revenue reached approximately RMB 1.474 billion, representing a year-on-year growth of 18.4% [1] - The net profit for the same period was approximately RMB 343 million, reflecting a year-on-year decrease of 16.8% [1]

Group 1 - The core point of the article is that China Resources Pharmaceutical announced its subsidiary, China Resources Boya Biopharmaceutical, achieved total operating revenue of 1.474 billion RMB for the nine months ending September 30, 2025, representing a year-on-year growth of 18.4% [1] - The net profit for the same period was 343 million RMB, which reflects a year-on-year decline of 16.8% [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告 全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 （於香港註冊成立的有限公司） （股份代號：3320） 截至2025年9月30日止九個月的未經審核財務業績 於2025年10月27日，華潤博雅生物公佈其截至2025年9月30日止九個月的季 度報告。 華潤博雅生物製藥集團股份有限公司（「華潤博雅生物」）為一家於中華人民共 和國註冊成立的公司。華潤博雅生物的股份於深圳證券交易所上市。截至本 公告日期，華潤醫藥集團有限公司（「本公司」，連同其附屬公司合稱為「本集 團」）間接持有華潤博雅生物總股本約30.48%及總股本約41.79%表決權，並為 本公司的附屬公司。 1 於2025年10月27日，華潤博雅生物公佈其截至2025年9月30日止九個月的季度 報告（「華潤博雅生物未經審核財務資料」）。下表載列華潤博雅生物未經審核 財務資料的主要財務資料： 截至9月30日止九個月 | | 2025年 | 2024年 | | --- | --- | --- | | | （ ...

Core Viewpoint - China Resources Pharmaceutical (03320.HK) reported a total revenue of approximately RMB 21.986 billion for the nine months ending September 30, 2025, reflecting a year-on-year increase of 11.38%. However, the net profit was approximately RMB 2.899 billion, showing a year-on-year decline of 10.64% [1]. Group 1 - The total revenue for the nine-month period reached approximately RMB 21.986 billion [1] - Year-on-year revenue growth was recorded at 11.38% [1] - The net profit for the same period was approximately RMB 2.899 billion [1] Group 2 - The net profit experienced a decline of 10.64% compared to the previous year [1]

Group 1 - The core viewpoint of the article is that China Resources Pharmaceutical (03320) reported its financial performance for the first three quarters of 2025, showing a mixed result with revenue growth but a decline in net profit [1] Group 2 - The total operating revenue for the first three quarters is approximately 21.986 billion yuan, representing a year-on-year increase of 11.38% [1] - The net profit for the same period is approximately 2.899 billion yuan, reflecting a year-on-year decrease of 10.65% [1]